Context Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Context Therapeutics (Nasdaq: CNTX), a biopharmaceutical company focused on T cell engagers for solid tumors, has announced its participation in three major upcoming investor conferences in February and March 2025:

• B. Riley Securities Precision Oncology & Radiopharma Conference: Two panel discussions scheduled for February 28, 2025, at 8:00 a.m. and 10:00 a.m. ET in New York

• TD Cowen 45th Annual Healthcare Conference: Presentation scheduled for March 3, 2025, at 11:10 a.m. ET in Boston

• Leerink Partners Global Healthcare Conference: Fireside chat scheduled for March 10, 2025, at 10:00 a.m. ET in Miami

The company will also conduct one-on-one meetings with investors at each conference.

PHILADELPHIA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate in the following investor conferences:

• B. Riley Securities Precision Oncology & Radiopharma Conference: Panel discussions on Friday, February 28, 2025, at 8:00 a.m. and 10:00 a.m. ET in New York, NY.
  
• TD Cowen 45^th Annual Healthcare Conference: Presentation on Monday, March 3, 2025, at 11:10 a.m. ET in Boston, MA.
  
• Leerink Partners Global Healthcare Conference: Fireside chat on Monday, March 10, 2025, at 10:00 a.m. ET in Miami, FL.
  

Context will also participate in one-on-one meetings at each of the above conferences.

About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.

Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the Company and its employees to participate in and present at conferences, (ii) the potential benefits, characteristics, safety and side effect profile of our product candidates, and (iii) the likelihood data will support future development. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

Investor Relations Contact:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics Inc.
IR@contexttherapeutics.com

FAQ

What investor conferences will Context Therapeutics (CNTX) attend in February-March 2025?

Context Therapeutics will participate in three conferences: B. Riley Securities Precision Oncology & Radiopharma Conference (Feb 28), TD Cowen 45th Annual Healthcare Conference (Mar 3), and Leerink Partners Global Healthcare Conference (Mar 10).

When is Context Therapeutics (CNTX) presenting at the TD Cowen Healthcare Conference?

Context Therapeutics will present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025, at 11:10 a.m. ET in Boston, MA.

What type of meetings will CNTX hold at the 2025 healthcare conferences?

Context Therapeutics will participate in panel discussions, presentations, fireside chats, and one-on-one meetings with investors at all three conferences.

Where will Context Therapeutics' (CNTX) investor presentations take place in 2025?

The presentations will take place in New York (B. Riley Securities Conference), Boston (TD Cowen Conference), and Miami (Leerink Partners Conference).